Frankfurt
20.12.24
08:05 Uhr
0,140 Euro
0,000
0,00 %
0,00 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,167 | 0,173 | 21.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 04.12. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 229 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.11. | Mauna Kea Technologies: Raising Pancreatic Cancer Awareness Through Patient Voices | 45 | Business Wire | With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer
Regulatory News:
This Pancreatic Cancer Awareness Month... ► Artikel lesen | |
| 20.11. | Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador | 33 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased... ► Artikel lesen | |
| 13.11. | Mauna Kea Technologies Provides an Update on Its Recent Developments | 261 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides... ► Artikel lesen | |
| 06.11. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 220 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website:... ► Artikel lesen | |
| 17.10. | Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance | 294 | Business Wire | Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6 Billion a Year Market Opportunity
Regulatory... ► Artikel lesen | |
| 15.10. | Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales | 342 | Business Wire | Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses Q3 2024 Sales Growth of +24%1 Driven by New System Sales in the U.S. and Europe Official Launch of... ► Artikel lesen | |
| 04.10. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 360 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 01.10. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 222 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 16.09. | Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio | 225 | Business Wire | Recent clinical study published in Journal of Thoracic Disease supports the combination of Cellvizio with Electromagnetic Navigation Bronchoscopy to improve diagnosis and treatment of lung cancer... ► Artikel lesen | |
| 10.09. | Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio | 319 | Business Wire | Formal letter requests coverage of Cellvizio and its dedicated category I CPT Codes to significantly enhance early detection of Barrett's Esophagus and Esophageal Cancer Prevalence of Esophageal... ► Artikel lesen | |
| 09.08. | Mauna Kea Technologies: Monthly information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 435 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 25.07. | Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024 | 490 | Business Wire | Q2 2024 Sales Up 48% vs. Q1 but Down 20% Year-on-Year1 as U.S. Systems Sales Scheduled for the Second Half of 2024 and Temporary Reimbursement Reduction Impacting PPU Revenue U.S. PPU Volume... ► Artikel lesen | |
| 17.07. | Mauna Kea Technologies: Half-year Liquidity Contract Statement for H1 2024 With the Brokerage Firm Gilbert Dupont | 633 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 04.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 369 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.06. | Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances | 373 | Business Wire | CellTolerance is a unique science-based program designed with physicians and dietitians New data presented at Digestive Disease Week 2024 reinforces the program's unique clinical value for patients... ► Artikel lesen | |
| 13.06. | Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024 | 411 | Business Wire | Pancreatic cancer remains difficult to diagnose accurately using conventional methods often leading to late-stage diagnoses or unnecessary surgeries New publications confirm once more Cellvizio's... ► Artikel lesen | |
| 07.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 6, 2024 | 307 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 06.06. | Mauna Kea Technologies Announces Joint Venture in China Obtained Class II Medical Device Business License | 350 | Business Wire | JV now operational to start selling products in China
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based... ► Artikel lesen | |
| 30.05. | Mauna Kea Technologies Winner of "Best New Technology Solution - Oncology" MedTech Breakthrough Award | 337 | Business Wire | Prestigious international program recognizes standout digital health medical technology products and companies 2024 awards program included more than 4,500 nominations from all around the world
Regulatory... ► Artikel lesen |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA | 0,146 | -3,95 % | Sernova Corp.: Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025 | ||
| VITA 34 | 4,120 | +2,49 % | Original-Research: Vita 34 AG (von Montega AG): Vita 34 AG | Original-Research: Vita 34 AG - von Montega AG 27.11.2024 / 10:10 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,600 | +5,88 % | Geratherm Medical Aktie: Keine Überraschungen erwartet | Die Geratherm Medical AG verzeichnete in den vergangenen Tagen einen beachtlichen Kursanstieg von 28 Prozent. Der aktuelle Aktienkurs liegt bei 3,79 EUR (Stand: 14. Dezember 2024). Diese Entwicklung... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,998 | -3,67 % | Plus Therapeutics Inc.: Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium | ||
| ATOSSA THERAPEUTICS | 0,934 | +0,65 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density | 1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During... ► Artikel lesen | |
| MEDICLIN | 2,460 | +1,65 % | EQS-PVR: MEDICLIN AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MEDICLIN AG
MEDICLIN AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
09.12.2024 / 11:30 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-Q, Quarterly Report | ||
| LIFEWARD | 1,470 | -1,34 % | Lifeward-Direktor Joseph Turk erwirbt Unternehmensaktien im Wert von 10.140 US-Dollar | ||
| VERU | 0,625 | +2,12 % | Veru (NASDAQ:VERU) Receives "Buy" Rating from HC Wainwright | ||
| DIASORIN | 100,00 | -0,05 % | Milan: Major selling for DiaSorin | ||
| FRESENIUS | 33,200 | -0,84 % | Fresenius SE Aktie: Positiver Umsatztrend! | Die Fresenius SE-Aktie zeigt sich im aktuellen Handelsverlauf an der XETRA mit wechselhafter Tendenz. Nach einem Handelsstart bei 34,92 EUR bewegte sich der Kurs im Tagesverlauf zwischen verschiedenen... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 52,10 | -0,72 % | Nach Siemens-Energy-Boom: Startet als nächstes die Siemens-Healthineers-Aktie durch? | Ein starkes Schlussquartal und ein optimistischer Ausblick des Medizintechnikers Siemens Healthineers sollten der Aktie genug Rückenwind liefern, auf den Anleger gehebelt setzen können. So funktioniert's.... ► Artikel lesen | |
| GERRESHEIMER | 67,65 | -7,27 % | Gerresheimer: FDA erteilt "Tentative Approval" für Lasix von SQ Innovation® ONYU* | Düsseldorf (ots) - - Innovatives Kombinationsprodukt aus Furosemid und On-Body Drug Delivery Device- Device marktreif konzipiert, entwickelt und hergestellt von Gerresheimer- Patentierte Gerätetechnologie... ► Artikel lesen |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.
